Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Short-term Investments (2020 - 2025)

Insight Molecular Diagnostics' Short-term Investments history spans 5 years, with the latest figure at $729000.0 for Q3 2025.

  • For Q3 2025, Short-term Investments changed N/A year-over-year to $729000.0; the TTM value through Sep 2025 reached $729000.0, changed N/A, while the annual FY2022 figure was $433000.0, 52.1% down from the prior year.
  • Short-term Investments for Q3 2025 was $729000.0 at Insight Molecular Diagnostics, up from $441000.0 in the prior quarter.
  • Across five years, Short-term Investments topped out at $1.1 million in Q2 2021 and bottomed at $400000.0 in Q3 2022.
  • The 4-year median for Short-term Investments is $600000.0 (2022), against an average of $656000.0.
  • The largest annual shift saw Short-term Investments soared 222.58% in 2021 before it crashed 55.56% in 2022.
  • A 4-year view of Short-term Investments shows it stood at $904000.0 in 2021, then tumbled by 52.1% to $433000.0 in 2022, then increased by 1.85% to $441000.0 in 2023, then skyrocketed by 65.31% to $729000.0 in 2025.
  • Per Business Quant, the three most recent readings for IMDX's Short-term Investments are $729000.0 (Q3 2025), $441000.0 (Q3 2023), and $530000.0 (Q2 2023).